Roche And Trimeris, Inc. Provide Update On Development Of Needle-Free Administration For FUZEON®

NUTLEY, N.J. & MORRISVILLE, N.C.--(BUSINESS WIRE)--Roche and Trimeris, Inc. today provided an update on the companies’ development plans for administration of FUZEON® (enfuvirtide) with a needle-free injection device (Biojector® 2000, B2000).